This site is intended for healthcare professionals

SGLT2 inhibitors and cardiovascular outcomes in type 2 diabetes: VERTIS CV trial

Posted 29 Jul 2020

Dr Kevin Fernando

Dr Kevin Fernando summarises results from the cardiovascular outcomes trial of ertugliflozin presented at the American Diabetes Association’s 2020 congress, along with the implications for primary care.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page